XELOX versus FOLFOX6 as an adjuvant treatment in colorectal cancer: an economic analysis

Author： Maniadakis Nikos Fragoulakis Vasilios Pectasides Dimitrios Fountzilas George

ISSN： 1473-4877

Source： Current Medical Research and Opinion, Vol.25, Iss.3, 2009-03, pp. : 797-805

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Cost-Minimisation Analysis in First-Line Treatment of Metastatic Colorectal Cancer in France: XELOX versus FOLFOX-6

Oncology, Vol. 79, Iss. 3-4, 2011-02 ,pp. : 174-180

Karger

Access to resources Recommend Favorite

Intermittent versus continuous erlotinib with concomitant modified “XELOX” (q3W) in first‐line treatment of metastatic colorectal cancer

CANCER, Vol. 119, Iss. 23, 2013-12 ,pp. : 4145-4153

John Wiley & Sons Inc

Access to resources Recommend Favorite

Results of Adjuvant FOLFOX Regimens in Stage III Colorectal Cancer Patients: Retrospective Analysis of 667 Patients

Oncology, Vol. 84, Iss. 4, 2013-02 ,pp. : 240-245

Karger

Access to resources Recommend Favorite

Adjuvant FOLFOX Chemotherapy and Splenomegaly in Patients with Stages II–III Colorectal Cancer

Oncology, Vol. 76, Iss. 5, 2009-03 ,pp. : 363-368

Karger

Access to resources Recommend Favorite

TRAIL receptor agonist conatumumab with modified FOLFOX6 plus bevacizumab for first‐line treatment of metastatic colorectal cancer

CANCER, Vol. 119, Iss. 24, 2013-12 ,pp. : 4290-4298

John Wiley & Sons Inc

Access to resources Recommend Favorite